Targeted microbeads for attraction and induction of specific innate immune response in the tumor microenvironment

Vaccine

Volumn 28, Issue 45, 2010, Pages 7279-7287

  Shahar, Ehud ^a,b   Gorodetsky, Raphael ^b   Gaberman, Elena ^b   Aizenshtein, Elina ^a   Pitcovski, Jacob ^a,c  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL HAI COLLEGE   (Israel)

Author keywords

Cancer immunotherapy; HER2; Innate immunity; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MANNOSE; NANOCARRIER; TILTAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RNA TRANSCRIPTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MANNOSE; MICE; MICE, INBRED BALB C; MICROSPHERES; MONOCYTES; NEOPLASMS; RECEPTOR, ERBB-2; TOXICITY TESTS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957794648     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.083     Document Type: Article

References (37)

1. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
4. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
5. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380.
6. Kaptain S., Tan L.K., Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001, 10:139-152.
7. Cheung K.L., Graves C.R., Robertson J.F. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000, 26:91-102.
8. Reichert J.M., Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6:349-356.
9. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005, 353:1734-1736.
10. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., et al. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268.
11. Wang R.F., Miyahara Y., Wang H.Y. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008, 27:181-189.
12. Scheel B., Aulwurm S., Probst J., Stitz L., Hoerr I., Rammensee H.G., et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006, 36:2807-2816.
13. Gay N.J., Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007, 76:141-165.
14. Salaun B., Coste I., Rissoan M.C., Lebecque S.J., Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006, 176:4894-4901.
15. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999, 59:5429-5432.
16. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004, 6:88-95.
17. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
18. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
19. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006, 176:6624-6630.
20. El Andaloussi A., Sonabend A.M., Han Y., Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54:526-535.
21. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
22. Cassard L., Cohen-Solal J., Camilleri-Broet S., Fournier E., Fridman W.H., Sautes-Fridman C. Fc gamma receptors and cancer. Springer Semin Immunopathol 2006, 28:321-328.
23. Odeyale C.O., Kang Y.H. Biotinylation of bacterial lipopolysaccharide and its applications to electron microscopy. J Histochem Cytochem 1988, 36:1131-1137.
24. Vaya J., Aizenshtein E., Khatib S., Gefen T., Fassler M., Musa R., Krispel S., Pitcovski J. Mannosamine-Biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody-antigen interaction. Vaccine 2009, 27(49):6869-6876.
25. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-208.
26. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997, 71:142-147.
27. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18:89-95.
28. Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H., et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995, 25:340-347.
29. Huber D., Philipp J., Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992, 148:277-284.
30. Smith D.R., Kunkel S.L., Burdick M.D., Wilke C.A., Orringer M.B., Whyte R.I., et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994, 145:18-25.
31. O'Hagan D.T., Singh M., Ulmer J.B. Microparticle-based technologies for vaccines. Methods 2006, 40:10-19.
32. Seidenfeld J., Samsom D.J., Rothenberg B.M., Bonnell C.J., Ziegler K.M., Aronson N. HER2 testing to manage patients with breast cancer or other solid tumors. Evid Rep Technol Assess (Full Rep) 2008, 1-362.
33. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283-290.
34. Frederick P.J., Straughn J.M., Alvarez R.D., Buchsbaum D.J. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009, 113:384-390.
35. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
36. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
37. Gabrilovich D.I., The Neutrophils: New outlook for old cells 2005, Imperial College Press, London, p. 275-99. second ed.